Compare VIR & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIR | BCX |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.0M | 750.9M |
| IPO Year | 2019 | N/A |
| Metric | VIR | BCX |
|---|---|---|
| Price | $6.10 | $11.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $25.73 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 370.6K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.99% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $8.25 |
| 52 Week High | $14.45 | $9.90 |
| Indicator | VIR | BCX |
|---|---|---|
| Relative Strength Index (RSI) | 49.41 | 67.18 |
| Support Level | $5.73 | $10.64 |
| Resistance Level | $6.11 | $10.90 |
| Average True Range (ATR) | 0.39 | 0.18 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 28.57 | 88.71 |
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.